T-Cell Immunotherapy Market Size, Share, Opportunities And Trends By Type (Chimeric antigen receptor, T-cell receptor, Tumor-infiltrating lymphocyte), By Indication (Melanoma, Leukemia, Ovarian cancer, Others), And Geography - Forecasts From 2019 To 2024

T-Cell immunotherapy changes body immune cells, as in this the T-cell of the person is taken out and are changed genetically during the process and then the changed cells are grown in large numbers and are injected into the patient’s body so that they can fight cancer cells naturally. This CAR T-cell immunotherapy is a promising cancer treatment for patients and also due to the rising prevalence of cancer and lack of ideal biomarkers for early detection of cancer this therapy is considered as the driving factor for the growth of the market. According to World Health Organization cancer is responsible for an estimated 9.6 million deaths in 2018 and nearly 70% of the deaths from cancer occur in low and middle-income countries, so this therapy can help the patient fight the cancer cells without much trouble and due to the rapidly increasing research and development activities and technological advancements in cancer treatment the T-cell immunotherapy market is likely to increase. The future of the immunotherapy involves the personalized approach where the sample of the tumor will be taken and then after doing the research the personalized T-cells will be created for the particular person. However, side effects like CRS, neurologic problems and health issues associated with CAR T-Cell therapy is considered as the restraining factor for the growth of the market.

DRIVERS

Reliable and effective treatment with minimum side effects

Growing occurrence of cancer in both adults and children

RESTRAINTS

Neurological and CRS problems which occur during treatment.

High cost

INDUSTRY UPDATE

In August 2017, Gilead Sciences, Inc. acquired Kite Pharma for $11.9 billion, an industry leader in the field of cell therapy.

The major players profiled in the T-Cell Immunotherapy market include Cellular Biomedicine Group, Autolus Novartis, Gilead Sciences, Inc., Adaptimmune Therapeutics, Cellectis, Bluebird bio, Immunocore, Innovative Cellular Therapeutics, Iovance Biotherapeutics, Celgene

Segmentation

The T cell Immunotherapy market has been analyzed through the following segments:

By Type

Chimeric antigen receptor (CAR)

T-cell receptor (TCR)

Tumor-infiltrating lymphocyte (TIL)

By Indication

Melanoma

Leukemia

Ovarian cancer

Others

By Geography

North America

USA

Canada

Mexico

South America

Brazil

Argentina

Others

Europe

Germany

France

United Kingdom

Spain

Others

Middle East and Africa

Saudi Arabia

Israel

Others

Asia Pacific

China

Japan

South Korea

India

Others

1. INTRODUCTION

1.1. Market Overview

1.2. Market Definition

1.3. Scope of the Study

1.4. Currency

1.5. Assumptions

1.6. Base, and Forecast Years Timeline

2. RESEARCH METHODOLOGY

2.1. Research Design

2.2. Secondary Sources

3. EXECUTIVE SUMMARY

4. MARKET DYNAMICS

4.1. Market Segmentation

4.2. Market Drivers

4.3. Market Restraints

4.4. Market Opportunities

4.5. Porter’s Five Force Analysis

4.5.1. Bargaining Power of Suppliers

4.5.2. Bargaining Power of Buyers

4.5.3. Threat of New Entrants

4.5.4. Threat of Substitutes

4.5.5. Competitive Rivalry in the Industry

4.6. Life Cycle Analysis - Regional Snapshot

4.7. Market Attractiveness

5. T- CELL IMMUNOTHERAPY MARKET BY TYPE.

5.1. Chemeric antigen receptor (CAR) T-cell

5.2. T-cell receptor (TCR)

5.3. Tumor-infiltrating lymphocyte (TIL)

6. T-CELL IMMUNOTHERAPY MARKET BY INDICATION

6.1. Melanoma

6.2. Leukemia

6.3. Ovarian cancer

6.4. Others

7. T-CELL IMMUNOTHERAPY MARKET BY GEOGRAPHY

7.1. North America

7.1.1. USA

7.1.2. Canada

7.1.3. Mexico

7.2. South America

7.2.1. Brazil

7.2.2. Argentina

7.2.3. Others

7.3. Europe

7.3.1. Germany

7.3.2. France

7.3.3. United Kingdom

7.3.4. Spain

7.3.5. Others

7.4. Middle East and Africa

7.4.1. Saudi Arabia

7.4.2. Israel

7.4.3. Others

7.5. Asia Pacific

7.5.1. China

7.5.2. Japan

7.5.3. South Korea

7.5.4. India

7.5.5. Others

8. COMPETITIVE INTELLIGENCE

8.1. Company Benchmarking and Analysis

8.2. Recent Investment and Deals

8.3. Strategies of Key Players

9. COMPANY PROFILES

9.1. Cellular Biomedicine Group

9.2. Autolus Novartis

9.3. Gilead Sciences, Inc.

9.4. Adaptimmune Therapeutics

9.5. Cellectis

9.6. Bluebird bio

9.7. Immunocore

9.8. Innovative Cellular Therapeutics

9.9. Iovance Biotherapeutics

9.10. Celgene

LIST OF FIGURES

LIST OF TABLES

Cellular Biomedicine Group

Autolus Novartis

Gilead Sciences, Inc.

Adaptimmune Therapeutics

Cellectis

Bluebird bio

Immunocore

Innovative Cellular Therapeutics

Iovance Biotherapeutics

Celgene